Table 1.
Patient characteristics and treatment
| Number | (%) | |
|---|---|---|
| Total | 1981 | 100.0 |
| Age | ||
| < 35 | 70 | 3.5 |
| 35–49 | 554 | 28.0 |
| 50–59 | 713 | 36.0 |
| 60–69 | 501 | 25.3 |
| ≥ 70 | 143 | 7.2 |
| Mean, SD | 54.3 | 10.7 |
| Max, Min | 18 | 86 |
| Menopausal state | ||
| Premenopause | 698 | 35.2 |
| Postmenopause | 1283 | 64.8 |
| Tumor stage at initial diagnosis | ||
| TX | 5 | 0.3 |
| Tis | 27 | 1.4 |
| T0 | 8 | 0.4 |
| T1 | 637 | 32.2 |
| T2 | 1030 | 52.0 |
| T3 | 172 | 8.7 |
| T4 | 102 | 5.1 |
| Nodal status at initial diagnosis | ||
| NX | 4 | 0.2 |
| N0 | 1131 | 57.1 |
| N1 | 673 | 34.0 |
| N2 | 130 | 6.6 |
| N3 | 42 | 2.1 |
| NA | 1 | 0.1 |
| Tumor grade | ||
| 1 | 179 | 9.8 |
| 2 | 633 | 34.5 |
| 3 | 1021 | 55.7 |
| NA | 148 | 7.4 |
| ER/PgR status | ||
| ER and/or PgR positive | 895 | 45.9 |
| ER and PgR negative | 1057 | 54.1 |
| NA | 29 | 1.5 |
| HER2 status | ||
| IHC 3 | 1617 | 84.0 |
| IHC ≤ 2 FISH+ | 264 | 13.7 |
| FISH + | 43 | 2.2 |
| Not classified above | 57 | 2.9 |
| Neoadjuvant therapy performed | 702 | 35.4 |
| Adjuvant therapy performed | 1974 | 99.6 |
| Trastuzumab administration | ||
| Preoperative only | 26 | 1.3 |
| Pre- and postoperative | 440 | 22.2 |
| Postoperative only | 1515 | 76.5 |
| Hormonal therapy performed | 954 | 48.2 |
| Surgery | 954 | 48.2 |
| Partial mastectomy | 1021 | 51.6 |
| Mastectomy | 959 | 48.4 |
| NA | 1 | 0.1 |
| Radiotherapy performed | 1139 | 57.5 |
LN lymph node, ER estrogen receptor, PgR progesterone receptor, IHC immunohistochemical staining, FISH fluorescence in situ hybridization, NA not available